ATE557099T1 - Hpv cd8+ t-zell-epitope - Google Patents

Hpv cd8+ t-zell-epitope

Info

Publication number
ATE557099T1
ATE557099T1 AT04786554T AT04786554T ATE557099T1 AT E557099 T1 ATE557099 T1 AT E557099T1 AT 04786554 T AT04786554 T AT 04786554T AT 04786554 T AT04786554 T AT 04786554T AT E557099 T1 ATE557099 T1 AT E557099T1
Authority
AT
Austria
Prior art keywords
present
hpv
provides
cell epitopes
epitopes
Prior art date
Application number
AT04786554T
Other languages
English (en)
Inventor
Fiona Harding
Jeanette Mucha
Original Assignee
Genencor Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencor Int filed Critical Genencor Int
Application granted granted Critical
Publication of ATE557099T1 publication Critical patent/ATE557099T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
AT04786554T 2003-09-05 2004-08-23 Hpv cd8+ t-zell-epitope ATE557099T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50045203P 2003-09-05 2003-09-05
PCT/US2004/027263 WO2005025497A2 (en) 2003-09-05 2004-08-23 Hpv cd8+ t-cell epitopes

Publications (1)

Publication Number Publication Date
ATE557099T1 true ATE557099T1 (de) 2012-05-15

Family

ID=34312196

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04786554T ATE557099T1 (de) 2003-09-05 2004-08-23 Hpv cd8+ t-zell-epitope

Country Status (10)

Country Link
US (2) US7153659B2 (de)
EP (1) EP1660686B1 (de)
JP (1) JP4647606B2 (de)
CN (1) CN1846000B (de)
AT (1) ATE557099T1 (de)
AU (1) AU2004271951B2 (de)
CA (1) CA2536735C (de)
MX (1) MXPA06002311A (de)
NZ (1) NZ545364A (de)
WO (2) WO2005026192A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
ATE354645T1 (de) * 2002-12-20 2007-03-15 Chromagenics Bv Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
CN101090968B (zh) * 2004-11-08 2011-10-26 科罗迈吉尼科斯公司 高水平表达蛋白质的宿主细胞的选择
EP1877087B1 (de) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren und zusammensetzungen zur erzeugung einer verbesserten immunantwort auf ein menschliches papillomavirus-immunogen
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2010040847A2 (en) 2008-10-10 2010-04-15 Era Biotech, S.A. Recombinant protein bodies as immunogen-specific adjuvants
US20090117123A1 (en) * 2007-11-02 2009-05-07 National Health Research Institutes Immunopeptides of hpv e6 and e7 proteins
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
EP2418284A1 (de) 2010-08-13 2012-02-15 ERA Biotech, S.A. Polypeptidsequenzen zur Induzierung von Proteinkörpern
WO2012145509A2 (en) 2011-04-19 2012-10-26 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors, and viruses
US10161938B2 (en) 2013-12-27 2018-12-25 Roche Sequencing Solutions, Inc. Systematic discovery, maturation and extension of peptide binders to proteins
AU2016251501A1 (en) 2015-04-20 2017-10-19 F. Hoffmann-La Roche Ag Specific peptide binders to proteins identified via systemic discovery, maturation and extension process
JP7457642B2 (ja) * 2017-04-03 2024-03-28 ビオンテック ユーエス インコーポレイテッド タンパク質抗原およびその使用
CN115286698B (zh) * 2022-05-10 2023-09-01 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US20020187131A1 (en) 1995-01-31 2002-12-12 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
GB9624456D0 (en) * 1996-11-25 1997-01-15 Isis Innovation Assay method
US6962790B1 (en) * 1998-09-23 2005-11-08 University Of Massachusetts Medical Center Predictive assay for immune response
GB0017990D0 (en) * 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
DK1326961T3 (da) * 2000-09-15 2008-01-07 Ortho Mcneil Pharm Inc Sammensætninger og fremgangsmåder tl inducering af specifikke cytolytiske T-cellereaktioner
US20030003485A1 (en) * 2001-05-15 2003-01-02 Ludwig Institute For Cancer Research Methods for identifying antigens
EP1392357A2 (de) * 2001-05-18 2004-03-03 Powderject Vaccines, Inc. Impfstoffzusamensetzung
FR2837837B1 (fr) * 2002-03-28 2006-09-29 Roussy Inst Gustave Epitopes peptidiques communs a des antigenes d'une meme famille multigenique

Also Published As

Publication number Publication date
EP1660686B1 (de) 2012-05-09
WO2005026192A2 (en) 2005-03-24
JP4647606B2 (ja) 2011-03-09
CA2536735A1 (en) 2005-03-24
US7329498B2 (en) 2008-02-12
US20050181458A1 (en) 2005-08-18
WO2005025497A2 (en) 2005-03-24
US7153659B2 (en) 2006-12-26
CA2536735C (en) 2013-01-22
AU2004271951B2 (en) 2008-08-21
EP1660686A4 (de) 2009-07-22
MXPA06002311A (es) 2006-05-19
NZ545364A (en) 2009-06-26
WO2005026192A3 (en) 2005-05-12
JP2007503830A (ja) 2007-03-01
US20070128630A1 (en) 2007-06-07
EP1660686A2 (de) 2006-05-31
CN1846000A (zh) 2006-10-11
CN1846000B (zh) 2012-10-03
AU2004271951A1 (en) 2005-03-24
WO2005025497A3 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
EP1660686A4 (de) Hpv cd8+ t-zell-epitope
ATE426412T1 (de) Adjuvante influenza-vakzine
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
WO2007067681A3 (en) Immunostimulatory compositions and methods
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
EP1326633A4 (de) Zusammensetzung mit immunogenen mikroteilchen
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
ATE466084T1 (de) Hla-a24-restringiertes krebsantigenpeptid
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
CY1107457T1 (el) Εμβoλιο κατa του hpv
ATE419872T1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
DK1292328T3 (da) Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse
BRPI0607605A2 (pt) moléculas imunogênicas
WO2005046449A3 (en) Soluble tcr molecules and methods of use
GB2434367A (en) Improved vaccines
DE602005023488D1 (de) Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
WO2004031230A3 (en) Novel mhc ii associated peptides
BR0316670A (pt) Anticorpos quiméricos e humanizados para integrina (alfa)5ß1 que modulam a angiogênese
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
HK1041810A1 (zh) 增加免疫反应的可溶性共同刺激分子的用途
WO2004105681A3 (en) Cd4+ human papillomavirus (hpv) epitopes
WO2005023849A3 (en) Antigenic peptides of rabies virus and uses thereof
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole